# Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI

> **NCT03664180** · PHASE4 · COMPLETED · sponsor: **Beijing Anzhen Hospital** · enrollment: 2989 (actual)

## Conditions studied

- STEMI - ST Elevation Myocardial Infarction

## Interventions

- **DRUG:** Bivalirudin
- **DRUG:** Enoxaparin
- **DRUG:** Unfractionated heparin
- **DRUG:** Bivalirudin placebo
- **DRUG:** Enoxaparin placebo syringe
- **DRUG:** Unfractionated heparin placebo

## Key facts

- **NCT ID:** NCT03664180
- **Lead sponsor:** Beijing Anzhen Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-11
- **Primary completion:** 2022-11-23
- **Final completion:** 2022-11-23
- **Target enrollment:** 2989 (ACTUAL)
- **Last updated:** 2023-05-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03664180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03664180, "Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03664180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*